@article{oai:nagasaki-u.repo.nii.ac.jp:00004106,
 author = {Kanetaka, Kengo and Takatsuki, Mitsuhisa and Kuroki, Tamotsu and Hayashi, Tomayoshi and Fukuoka, Junya and Eguchi, Susumu},
 issue = {3},
 journal = {Acta medica Nagasakiensia},
 month = {Mar},
 note = {Background; The CD44 and CD133 expressions have been identified to be putative cancer stem cell (CSC) markers. Some reports have revealed a correlation between these CSC markers and a poor prognosis in the clinical setting. However, clinical impact of combined use of these markers has not been determinated in advanced gastric cancer.
Methods; Specimens were obtained from 73 patients with gastric cancer with invasion beyond the muscularis (T3/4a) who underwent curative gastrectomy. Immunohistochemically, tumors with more than 5% CD44-positive cells or at least one CD133-positive cancer cell were regard as being CSC marker-positive.
Results; Forty patients were CSC marker-positive. There were significant correlations between the CSC marker expression and the extent of lymphatic (p=0.04) and vessel invasion (p<0.001). The CSC marker-positive patients exhibitedpoor prognoses in both the overall (p=0.006) and disease-free survival analyses (p=0.019). Based on the results of the univariate analysis, the peritoneal CEA value, the extent of lymph node metastasis and CSC marker positivity were analyzed in the multivariate analysis. The results revealed that the extent of lymph node metastasis (p<0.001) and CSC marker positivity (p=0.04) were significant risk factors.
Conclusion; CSC marker positivity is an independent prognostic factor in patients with T3/4a gastric cancer., Acta medica Nagasakiensia, 59(3), pp.83-89; 2015},
 pages = {83--89},
 title = {Positivity for cancer stem cell markers, CD44 and CD133, is a useful biomarker for predicting the outcomes of patients with advanced gastric cancer},
 volume = {59},
 year = {2015}
}